Drs. Pimentel-Santos and Branco reply

To the Editor:

We appreciate the interest¹ in our report² in which *ANKH* polymorphisms were not identified as major determinants of susceptibility to ankylosing spondylitis (AS) and do not influence phenotypic characteristics of AS — age at disease onset or results of the Bath AS Disease Activity Index, Bath AS Functional Index, or modified Stoke Ankylosing Spondylitis Spine Score².

Occurrence of renal stones was not evaluated in our study of Portuguese patients with AS². There are some data showing an increased prevalence of renal stone formation in patients with AS/spondyloarthritis^{3,4}. Moreover it was described that the transmembrane protein *ANKH* is expressed in kidney tissues such as cilia and basal body structures, as well as epithelial cells⁵. Considering the function of *ANKH* as a pyrophosphate transporter and regulator of tissue calcification, a potential role in renal stone formation represents an interesting hypothesis for study. However, no association between *ANKH* and renal stone formation was seen in the study described by Korkmaz and Sayer¹; it is important to mention that that study was clearly underpowered to elicit evidence for this kind of association.

Despite weak positive associations described by some authors^{6,7}, there is convincing evidence that the *ANKH* gene has no significant role in AS^{2,8}. In addition, no association was identified with this gene and AS susceptibility in large studies using high numbers of nonsynonymous SNP⁹ or in genome-wide association studies¹⁰.

There are several concerns regarding the studies focusing on *ANKH* variants: (1) methodological differences (ethnicity, case ascertainment approaches, and *ANKH* marker variants analyzed); and (2) all of them were underpowered to detect genes with small effects consistently. Thus further studies are needed to reach definitive conclusions.

FERNANDO MANUEL PIMENTEL-SANTOS, MD, MSc, CEDOC, Faculdade de Ciências Médicas da Universidade Nova de Lisboa; I Instituto de Biotecnologia e Bioengenharia, Centro de Genómica e Biotecnologia, da Universidade de Trás-os-Montes e Alto Douro, Vila Real; Serviço de Reumatologia, Centro Hospitalar Lisboa Ocidental (CHLO), Hospital de Egas Moniz EPE, Lisbon; JAIME C. BRANCO, MD, PhD, CEDOC, Faculdade de Ciências Médicas da Universidade Nova de Lisboa; Serviço de Reumatologia, CHLO, Hospital de Egas Moniz EPE, Lisbon, Portugal. Address correspondence to Dr. Pimentel-Santos, Faculdade de Ciências Médicas, Universidade Nova de Lisboa - CEDOC, Campo Mártires da Pátria, n°130, Lisbon 1169-056 Portugal; E-mail: pimentel.santos@gmail.com

REFERENCES

1. Korkmaz C, Sayer JA. *ANKH* and renal stone formation in ankylosing spondylitis. *J Rheumatol* 2012;39:1756.
2. Pimentel-Santos FM, Ligeiro D, Matos M, Mourão AF, de Sousa EV, Pinto P, et al. *ANKH* and susceptibility to and severity of ankylosing spondylitis. *J Rheumatol* 2012;39:131-4.
3. Canales BK, Leonard SM, Singh JA, Orzano IM, Zimmermann B, Weiland D, et al. Spondyloarthropathy: an independent risk factor for kidney stones. *J Endourol* 2006;20:542-6.
4. Korkmaz C, Özcan A, Akçar N. Increased frequency of ultrasonographic findings suggestive of renal stones in patients with ankylosing spondylitis. *Clin Exp Rheumatol* 2005;23:389-92.
5. Carr G, Mochhala SH, Eley L, Vandewalle A, Simmons NL, Sayer JA. The pyrophosphate transporter *ANKH* is expressed in kidney and bone cells and colocalises to the primary cilium/basal body complex. *Cell Physiol Biochem* 2009;24:595-604.
6. Furuichi T, Maeda K, Chou CT, Liu YF, Liu TC, Miyamoto Y, et al. Association of the *MSX2* gene polymorphisms with ankylosing spondylitis in Japanese. *J Hum Genet* 2008;53:419-24.
7. Tsui HW, Inman RD, Paterson AD, Reveille JD, Tsui FW. *ANKH* variants associated with ankylosing spondylitis: Gender differences. *Arthritis Res Ther* 2005;7:513-25.
8. Timms AE, Zhang Y, Bradbury L, Wordsworth BP, Brown MA. Investigation of the role of *ANKH* in ankylosing spondylitis. *Arthritis Rheum* 2003;48:2898-902.
9. Wellcome Trust Case Control Consortium; Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. *Nat Genet* 2007;39:1329-37.
10. Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, et al; Spondyloarthritis Research Consortium of Canada (SPARCC), Australo-Anglo-American Spondyloarthritis Consortium (TASC); Wellcome Trust Case Control Consortium 2 (WTCCC2). Interaction between *ERAP1* and *HLA-B27* in ankylosing spondylitis implicates peptide handling in the mechanism for *HLA-B27* in disease susceptibility. *Nat Genet* 2011;43:761-7.

J Rheumatol 2012;39:8; doi:10.3899/jrheum.120376